Gonadotropin-releasing hormone agonist
- Gonadotropin-releasing hormone agonist
- Accession Number
- DBCAT002742 (DBCAT000050, DBCAT002088, DBCAT002435)
A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND.
- ATC Classification
Drug Drug Description Leuprolide A peptide-based GnRH receptor superagonist used for the palliative treatment of prostate cancer, uterine leiomyomata, endometriosis, and central precocious puberty. Goserelin A synthetic analog of luteinizing hormone-releasing hormone used to treat breast cancer and prostate cancer by reducing secretion of gonadotropins from the pituitary. Buserelin A LHRH agonist used for the palliative treatment of hormone-dependent advanced carcinoma of the prostate gland in males and treatment of endometriosis in females. Triptorelin A GnRH agonist indicated for the palliative treatment of advanced prostate cancer. Nafarelin A gonadotropin releasing hormone agonist used to treat central precocious puberty. Gonadorelin A synthetic GnRH used to test the function of gonadotropes and the pituitary. Deslorelin Deslorelin acetate is an injectable gonadotropin releasing hormone super-agonist also known as an LHRH agonist. It stops the production of sex hormones. Histrelin A GnRH agonist found in subcutaneous implants used for the treatment of pediatric patients with central precocious puberty and the palliative treatment of advanced prostate cancer.
- Drugs & Drug Targets